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Abstract
HLA matching is a critical factor for successful allogeneic hematopoietic stem cell transplantation. For unrelated donor
searches, matching is usually based on high-resolution typing at five HLA loci, looking for a 10/10 match. Some studies
have proposed that further matching at the haplotype level could be beneficial for clinical outcome. In this study, we
determined the phased haplotypes of 291 patients using family members and segregation analysis. The sum of ranks of the
haplotypes carried by patients was used as a surrogate predictor of a successful unrelated donor search. The putative impact
of haplotypes was then analyzed in a cohort of 211 recipients transplanted with 10/10 matched unrelated donors. A logistic
regression analysis showed a highly significant effect of the haplotypes in the outcome of a search, but we did not find any
significant effect on overall survival, graft versus host disease or relapse/progression following HSCT. This study provides
useful data for the optimization of unrelated bone marrow donor searches, but does not confirm previous reports that
matching at the haplotype level has a clinical impact following HSCT. Due to the extreme polymorphism of HLA genes,
further studies are warranted to better understand the many factors at play.
Introduction
Human leukocyte antigen (HLA) matching between reci-
pients and donors is a prerequisite for successful allogeneic
hematopoietic stem cell transplantation (HSCT), notably to
avoid graft versus host disease (GVHD) as main post-
transplant complication. Although new protocols for
selecting donors are increasingly sought, even across the
histocompatibility barrier [1–3], the gold standard is to look
first for an HLA identical sibling. If such a genotypically
identical sibling cannot be found, the preferred alternative is
to search for a 10/10 or 12/12 phenotypically matched
unrelated donor (MUD) [4, 5]. With unrelated donors,
matching is based on high-resolution typing at HLA-A, B,
C, DRB1, DQB1 and possibly DPB1 and DRB3/4/5 with
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no consideration given to putative haplotype matching
between the recipient and his donor. However, even with
well-matched unrelated donors, risks of transplant-related
mortality are higher as compared to matched sibling donors
because of minor histocompatibility antigens (mHA) spread
across the whole genome and non-HLA linked poly-
morphisms (e.g. single nucleotide polymorphisms (SNPs),
expression quantitative trait loci (eQTL), microsatellites)
within the extended HLA region [6–12]. Thus, in an attempt
to leverage such a hurdle, several studies have suggested a
possible beneficial impact of HLA haplotype matching at
reducing post-transplantation complications in patients
transplanted with 10/10 MUD [13–16]. A haplotype defines
which allele belongs to which copy of the two chromo-
somes, or alternatively, which alleles segregate together on
a single chromosome. In practice, HLA haplotypes can
either be phased unambiguously by family segregation
analysis or imputed statistically from genotype data and
HLA frequencies in populations. The underlying hypothesis
is that if a recipient and his unrelated donor are matched for
the same common haplotypes, such haplotypes could carry
more conserved DNA segments shared by descent
(including at nearby favorable SNPs) compared to rare
haplotypes present in the population.
Besides the extremely high level of polymorphism,
complex patterns of association define classical HLA genes.
Some pairs like B~C and DRB1~DQB1 are found in tight
association on chromosome 6 [17], whereas other loci are
defined by weaker (HLA-A) or non-significant linkage
(HLA–DPB1), due to more distant location or recombina-
tion hotspots [18, 19]. These characteristics represent a
significant hindrance to determine HLA multi-locus haplo-
types and their corresponding frequencies [20]. In con-
sequence, powerful methodologies have been developed to
assess haplotype frequencies in various populations [21, 22]
and in large cohorts of unrelated donors [23], but such
approaches need to rely on representative sample sizes and
on assumptions that are not always met in practice [22]. In
this context, the availability of families typed at several
HLA loci for the purpose of HSCT-related donor searches
has provided informative data to characterize HLA haplo-
types by segregation analysis [24–26], contributing to
define the probability of finding suitable unrelated donors
[27–29] or to study clinical outcome of unrelated HSCT
[13]. However, studies using phased haplotypes remain
scarce in the literature and phased HLA haplotypes are
needed in more populations because HLA frequencies vary
significantly according to geography [30–32].
The first aim of this study was to investigate haplotype
segregation in a large cohort of patients and their family
living in Switzerland. This would allow us to constitute a
reference panel to help in optimizing future unrelated donor
searches for the significant proportion of patients in need of
a transplantation with no HLA identical sibling [5]. The
second aim was to use these phased haplotypes for pre-
dicting the outcome of unrelated donor searches for patients
waiting for a HSCT. Within the last aim, we analyzed
HSCT outcomes in a group of recipients transplanted with
10/10 MUD and we tested their HLA haplotypes fre-




The phased haplotypes of individuals living in Switzerland
were determined from the HLA-A, B and DRB1 typing of
843 patients and 2132 family members (Figure S1),
allowing to constitute a cohort of 291 patients with high-
resolution phased haplotypes. High-resolution typing was
also performed at HLA-C and DQB1 for 290 of these
patients as potential candidates for an unrelated donor
search. Allogeneic HSCT was performed in 140 patients,
including 101 with 10/10 MUD and 39 with mismatched
donors. To enlarge the clinical cohort, 111 recipients of 10/
10 MUD with family segregation data were obtained from
the other Swiss transplant centers (Table S1). This study
was approved by the ethical committee of the institution




Haplotype frequencies were either estimated by direct
counting on 291 patients based on segregating haplotypes
or by using an implementation of the expectation–max-
imization (EM) algorithm on 6114 unrelated Swiss donors
based on multi-locus unphased genotypes. Hardy–Weinberg
(HW) equilibrium assumptions were assessed using a nested
likelihood procedure. Global linkage disequilibrium
between pairs of loci was tested using a resampling pro-
cedure and linkage disequilibrium for individual haplotypes
was determined using standardized residuals. All these
analyses were performed with the hla-net.eu Gene[RATE]
tools [21, 33].
Unrelated donor searches
The sum of ranks of the phased haplotypes carried by each
patient was considered as a surrogate predictor of a suc-
cessful search (i.e. finding at least one 10/10 MUD). Hap-
lotypes were ranked based on high-resolution haplotype
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frequencies estimated on 6114 donors from the Swiss reg-
istry (SBSC). The choice of the sum of haplotype ranks is
analogous to a non-parametric approach with the goal of not
relying directly and too heavily on estimated haplotype
frequencies as search outcome determinants. Confusion
matrices, logistic regression and receiver operating char-
acteristic (ROC) curve were generated in R (version 3.5.0)
using the packages ggplot2, reshape, caret and ROCR.
Clinical outcome
We followed the reasoning applied by Joris et al. [13] to
consider that a low haplotype ranking in a recipient (i.e.
carrying one or two frequent haplotypes) was a good proxy
for haplotype matching with his 10/10 MUD. As unrelated
donors are selected at a worldwide scale, SBSC frequencies
were contrasted with frequencies estimated on donors from
the United States [34]. Recipients were subdivided into
categories based on the ranking of their haplotypes, using
rank 50 and rank 20 as two distinct cut-offs to classify
haplotypes as common or rare, and were subsequently
analyzed in separate models for survival (see Tables S1
and S2, Table 2 and Fig. 2 for the categories considered).
Obviously, the chosen cut-offs and categories are arbitrary
to a degree, but this provided a compromise to the very
heterogeneous values proposed in previous studies for
defining common haplotypes [13, 15]. It also allowed to
consider alternative groups while keeping sufficient and
meaningful numbers of patients within each one. Further-
more, we would expect that a strong effect of haplotypes on
clinical outcome should be robust and consistent across
different cut-offs to be really considered as a relevant
parameter. Secondary outcomes (relapse/progression, acute
GVHD, chronic GVHD and survival status) were tested by
univariate analyses and by estimating cumulative incidence.
Cox proportional-hazards models were used to evaluate the
effect of potential confounding variables, in addition to
haplotypes, on overall survival, progression-free survival,
relapse/progression and chronic GVHD. Because of missing
dates for the onset of acute GVHD, a logistic regression was
performed instead. The parameters considered were DPB1
matching, source of stem cells, year of treatment, type and
stage of disease, patient age at transplantation, transplanta-
tion center, T-cell depletion, conditioning, cytomegalovirus
(CMV) serological status and recipient/donor gender com-
bination. Donor age was not analyzed because of missing
data. HLA–DPB1 matching was also investigated as an
explanatory variable for overall survival (OS), for occur-
rence of acute GVHD and for relapse/progression. These
analyses were generated with SPSS on a total of 211 reci-
pients (Table S1) with parameters equally distributed across
groups except for recipient/donor gender (Table S2). The
median waiting time was 116 days between donor search
and transplantation with no significant difference among
recipients according to haplotype groups.
Results
HLA haplotypes determination
A total of 420 distinct high-resolution HLA-A~B~DRB1
haplotypes were phased by segregation analysis in the 291
patients and HW equilibrium was not rejected at any locus.
The most frequent haplotypes are listed in Table 1. None of
them reached a frequency of 5% and only seven had a
frequency >1%, with most haplotypes observed just twice
or once in the cohort (Table S3). The three loci were not
significantly associated to each other (p-value of 1 accord-
ing to the likelihood-ratio test, no extreme value according
to parametric resampling for global linkage disequilibrium).
This was in agreement with the observation that only few
haplotypes were in complete linkage across the three loci
(Tables 1 and S3).
As family data are seldom available to confirm haplotype
frequencies when samples are typed for HLA, we also
estimated haplotype frequencies on our data by using the
EM algorithm without accounting for phase information
and we compared the results with those of our segregation
analysis. It showed us that 265 haplotypes were simulta-
neously assigned by both approaches, while 155 were
assigned by segregation analysis only and 258 were found
by EM only. This represented a low concordance (39%)
between the two approaches. In addition, the haplotypes
assigned by both approaches sometimes exhibited fre-
quency differences. As an example, haplotype
A*02:01~B*08:01~DRB1*03:01 exhibits a frequency of
0.52% through segregation analysis, whereas it reaches an
overestimated frequency of 1.53% through EM; this is
because its alleles frequently occur simultaneously at the
genotype level but are most often not linked on the same
chromosome (Figure S2).
The HLA-A~B~DRB1 phased haplotypes in the 291
patients were ranked according to their frequencies esti-
mated on the 6114 Swiss volunteer donors (Tables 1
and S3). Both sets of data were cross-tabulated in order to
predict the most probable extended HLA haplotypes in
Switzerland as listed in Table S4.
Predicting 10/10 matched unrelated donors
searches
Using a logistic regression model with the sum of ranks as
an explanatory variable (Fig. 1a), we could show a sig-
nificant association to search outcome (p= 2.25e−14).
We then investigated the best rank cut-off to predict
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search outcome with good sensibility and specificity, and
the inspection of boxplots (Fig. 1b) suggested a sum of
1000, i.e. corresponding to patients carrying at least one
very rare haplotype not seen in SBSC or carrying two
infrequent haplotypes. To confirm this preliminary
assessment, we ran an ROC curve analysis, which showed
that a sum of 1000 was a good trade-off between true and
false-positive rates (Figure S3). Using this cut-off value of
1000, we achieved a sensitivity of 0.71 and a specificity of
0.72. Most false positives (i.e. no 10/10 MUD found
despite a sum <1000) were due to patients carrying rare
allele(s) or unusual B~C or DRB1~DQB1 association(s),
which significantly impaired the chances of finding a
donor. By contrast, false negatives (i.e. at least one 10/10
MUD found despite a sum >1000) were often observed in
patients carrying one very frequent haplotype besides the
rare one, explaining why a donor could still be found in
this specific constellation.
HLA haplotypes and clinical outcome following
HSCT
The univariate analyses did not reveal a significant effect of
haplotypes on overall survival (Table 2 and Fig. 2) or on
other outcomes such as GVHD (Table 2). Moreover,
cumulative incidence for relapse and GVHD was not dif-
ferent across haplotype groups (Figure S4). By contrast,
better DPB1 matching was slightly, although significantly,
associated to less acute GVHD (p= 0.02) and higher
relapse/progression rate (p= 0.03), but not to better overall
survival (Table 2).
Haplotypes were never significant in multivariate ana-
lyses. Recipients’ age, stage of disease and transplantation
center were significantly associated to survival (Tables 3
and S5), progression-free survival and relapse/progression
(results not shown). In models inspected, older recipients
and/or recipients with an advanced disease had a lower
Table 1 Most frequent HLA-A~B~DRB1 phased haplotypes and linkage disequilibrium among allele pairs in the cohort of 291 patients
















A*01:01~B*08:01~DRB1*03:01 0.0326 19 8.38 4.08 11.67 1 1 2 40 2
A*03:01~B*07:02~DRB1*15:01 0.0206 12 3.93 2.11 9.71 2 2 7 NA 3
A*02:01~B*07:02~DRB1*15:01 0.0172 10 0.31 0.73 9.71 5 4 41 615 9
A*03:01~B*35:01~DRB1*01:01 0.0137 8 4.31 2.96 8.38 4 8 149 75 23
A*29:02~B*44:03~DRB1*07:01 0.012 7 11.31 3.50 9.25 6 5 9 1257 1
A*01:01~B*57:01~DRB1*07:01 0.012 7 6.78 0.36 5.85 8 7 58 8 22
A*26:01~B*38:01~DRB1*13:01 0.0103 6 9.71 2.26 4.56 42 53 NA NA 162
A*02:01~B*44:02~DRB1*04:01 0.0086 5 3.37 2.53 4.24 3 3 10 1292 46
A*30:01~B*13:02~DRB1*07:01 0.0086 5 11.98 3.98 7.17 10 10 178 4 16
A*24:02~B*07:02~DRB1*15:01 0.0086 5 1.14 0.67 9.71 13 13 337 183 72
A*02:01~B*51:01~DRB1*11:01 0.0086 5 2.38 0.08 3.47 15 28 122 496 27
A*01:01~B*08:01~DRB1*15:01 0.0086 5 8.38 −0.23 −0.17 25 25 544 NA NA
A*24:02~B*08:01~DRB1*03:01 0.0086 5 0.34 0.63 11.67 47 34 1379 268 42
A*02:01~B*15:01~DRB1*04:01 0.0069 4 2.22 2.53 7.06 9 6 21 1419 39
A*02:01~B*18:01~DRB1*03:01 0.0069 4 0.22 0.17 2.82 68 71 80 NA 40
A*02:01~B*40:01~DRB1*13:02 0.0052 3 1.11 −0.35 3.16 7 9 81 NA 554
A*02:01~B*08:01~DRB1*03:01 0.0052 3 −1.86 0.17 11.67 17 11 20 NA 18
A*02:01~B*18:01~DRB1*11:04 0.0052 3 0.22 0.08 5.69 24 33 NA NA 70
A*31:01~B*40:01~DRB1*04:04 0.0052 3 5.40 4.09 6.07 27 20 98 1264 137
A*02:01~B*51:01~DRB1*08:01 0.0052 3 2.38 0.55 1.78 29 73 245 NA 203
A*32:01~B*44:03~DRB1*07:01 0.0052 3 2.06 1.81 9.25 120 291 NA 236 234
A*01:01~B*15:17~DRB1*13:02 0.0052 3 4.04 2.70 8.41 210 327 NA 55 284
A*02:01~B*13:02~DRB1*13:01 0.0052 3 −0.04 0.09 1.15 333 NA 1131 NA NA
LD: pairwise linkage disequilibrium as defined by standardized residuals; values ≥2 correspond to a significant association. Haplotypes in complete
linkage (i.e. across the three loci) are shown in bold.
Rank of haplotypes estimated in 6114 volunteer donors from the Swiss registry (SBSC) and in four large groups (EUR: donors of European
descent, AFA: donors of African descent, API: donors of Asian descent, HIS: donors of South American descent) of volunteer donors from the
National Marrow Donor Program (NMDP) (ref. 34)
NA not available
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chance of survival and progression-free survival but a
higher risk of relapse/progression. Furthermore, in agree-
ment with the results obtained in the univariate setting,
DPB1 matching was not associated to better survival
(Tables 3 and S5), but was a significant risk factor for
relapse/progression and progression-free survival when not
accounting for conditioning (results not shown). The other
variables considered were never found to be significant,
except type of disease in the models for relapse/progression
because of a higher risk in recipients suffering from acute
leukemia. Regarding chronic GVHD, no variable was sig-
nificant. Logistic regression for acute GVHD revealed small
but significant effects of T-cell depletion and source of cells
and minor differences between acute leukemia and the other
diseases (results not shown).
Discussion
HLA haplotype determination is usually not based on
family segregation, but relies on estimations performed with
state-of-the-art EM algorithm implementations [35, 36].
Interestingly, the comparative analysis undertaken in this
study showed that only a mere 39% assignation con-
cordance was achieved between the real phased haplotypes
in our cohort and a “blind” estimation with the EM
algorithm. The discrepancies were mostly due to rare
haplotypes and this problem has recently been discussed
[20], but this also concerned the frequent haplotype
Table 2 Clinical outcome
following HSCT: summary of
univariate analyses
Outcome Explanatory variable Test Statistic df p-Value
Overall survival (OS) geno50 Log-Rank 1.72 2 0.42
geno50.bis Log-Rank 1.54 1 0.22
geno20 Log-Rank 1.21 1 0.27
Relapse/progression geno50 χ2 2.32 2 0.31
geno50.bis Fisher – – 0.68 (two-sided)
geno20 Fisher – – >0.99 (two-sided)
aGVHD geno50 χ2 0.69 4 0.95
geno50.bis χ2 0.5 2 0.78
geno20 χ2 0.63 2 0.73
cGVHD geno50 χ2 1.38 2 0.5
geno50.bis Fisher – – 0.83 (two-sided)
geno20 Fisher – – 0.27 (two-sided)
Survival status at this date geno50 χ2 7.55 4 0.11
geno50.bis χ2 6.59 2 0.04
geno20 χ2 1.08 2 0.58
Overall survival (OS) DPB1 matching Log-Rank 0.52 2 0.77
aGVHD DPB1 matching χ2 7.64 2 0.02
Relapse/progression DPB1 matching χ2 7.01 2 0.03
Geno50: recipients carrying 2, 1 or 0 common haplotypes with a frequency ≤ rank 50; geno50.bis: recipients
carrying 2 common haplotypes with a frequency ≤ rank 50 versus recipients carrying any rare haplotypes
with a frequency > rank 50; geno20: recipients carrying 0 or 1 rare haplotype versus recipients carrying 2
rare haplotypes with a frequency > rank 20
aGVHD acute graft vesus host disease, cGVHD chronic graft versus host disease, df degrees of freedom
No
Yes
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Fig. 1 Unrelated search outcome with the sum of haplotype ranks used
as an explanatory variable, a logistic regression on the data represented
by the black line with confidence interval in light gray, b box-and-
whisker plots
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A*02:01~B*08:01~DRB1*03:01. This illustrates the use-
fulness of family data for characterizing high-resolution
multi-locus haplotypes [26] when sample sizes are not huge
(meaning hundred thousand, or even millions of indivi-
duals). In addition, the use of next-generation sequencing
(NGS) technologies is expected to increase the variability of
high-resolution haplotypes. For instance, our data at third-
field-level resolution includes A*02:01:01~B*08:01:01
~DRB1*03:01:01 and A*02:01:01~B*08:01:02~DRB1*
03:01:01 haplotypes.
In the unrelated setting, the probability of finding a 10/10
matched donor is largely determined by haplotype fre-
quencies, our analyses thus agree with previous publications
[13, 27–29, 37–39]. Accurate prediction allows to define the
optimal strategy to find the best suitable donor, whether a
matched unrelated, mismatched unrelated or a haploiden-
tical donor [40, 41].
By exploring several different models, we show that the
presence of frequent haplotype(s) in the patients had no
impact on HSCT outcome and thus partly differ from pre-
vious studies. Notably, Petersdorf et al. [15] found that
haplotype matching between donors and recipients was
associated with less grade 3–4 acute GVHD and with a
higher risk of disease recurrence, but not with overall sur-
vival. In their publication, however, the haplotypes were
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Fig. 2 Kaplan–Meier plots for the different genotype categories con-
sidered regarding haplotype frequency and HSCT outcome. Geno50:
recipients carrying 2, 1 or 0 common haplotypes with a frequency ≤
rank 50; geno50.bis: recipients carrying 2 common haplotypes with a
frequency ≤ rank 50 versus recipients carrying any rare haplotypes
with a frequency > rank 50; geno20: recipients carrying 0 or 1 rare
haplotype versus recipients carrying 2 rare haplotypes with a fre-
quency > rank 20
Table 3 Cox regression model
for overall survival with geno50
95.0% CI for
Exp(B)
Explanatory variable B SE Wald df Sig. Exp(B) Lower Upper
TX center 22.715 3 0
2 −0.592 0.344 2.965 1 0.085 0.553 0.282 1.085
3 1.017 0.31 10.754 1 0.001 2.765 1.506 5.078
4 0.789 0.69 1.309 1 0.253 2.201 0.57 8.509
Age 10.77 3 0.013
Age (20–40) 1.02 0.543 3.528 1 0.06 2.773 0.957 8.041
Age (40–60) 1.03 0.473 4.735 1 0.03 2.801 1.108 7.081
Age (>60) 1.688 0.528 10.206 1 0.001 5.409 1.92 15.236
Disease stage 11.286 2 0.004
Disease stage (intermediate) 0.268 0.285 0.888 1 0.346 1.308 0.748 2.285
Disease stage (advanced) 1.042 0.317 10.828 1 0.001 2.835 1.524 5.272
DPB1 MM 0.628 2 0.731
DPB1 MM (1 MM) 0.084 0.319 0.07 1 0.791 1.088 0.583 2.032
DPB1 MM (2 MM) −0.145 0.353 0.169 1 0.681 0.865 0.433 1.729
geno50 0.805 2 0.669
geno50 (1 common haplotype) 0.291 0.377 0.595 1 0.44 1.337 0.639 2.799
geno50 (0 common haplotype) 0.376 0.428 0.771 1 0.38 1.456 0.63 3.368
Baseline for TX center = 1, for age = <20, for disease stage = early, for DPB1 MM = 0 MM, for geno50 =
2 common haplotypes. MM mismatch, TX transplant
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DNA microarray method that defines the physical linkage
between HLA-A, B and DRB1 alleles, whereas our study
determined them from family segregation analysis in reci-
pients with indirect imputation of haplotype matching with
their MUDs. A second difference between the two studies is
the over representation in the former of the frequent hap-
lotype A*01:01~B*08:01~DRB1*03:01, which is found in
about 11% of the 246 donor–recipient pairs analyzed and
which is always matched except in three cases, thus strongly
contributing statistically to the results. In our cohort, this
haplotype is present in only 6% of the 211 recipients. A
second publication based on a large Japanese cohort [14]
showed that among the three major conserved extended
haplotypes (HP-P1, 2 and 3) found in Japanese, HP-P2
significantly reduced the risk of grade 2–4 acute GVHD,
while HP-P3 tended to increase this risk, suggesting that
conserved haplotypes may be beneficial or deleterious for
the clinical outcome. In a third publication [13], an effect of
haplotypes was seen only on the incidence of ≥grade 2 acute
GVHD (survival or relapse were not significant) and only in
the category “1 or 2 frequent haplotype(s) (FH)” (but not in
the categories 1 FH and 2 FH taken individually). More-
over, the “1 of 2 FH” category was not associated with
GVHD in univariate analysis and was only significant (p=
0.026) when adjusting for other factors in a multivariate
model.
The controversial effect of haplotype matching might be
related to methodological heterogeneity at defining common
haplotypes, limitations to achieve sufficient statistical power
and perhaps more likely to different impacts of individual
haplotypes.
In 10/10 matched unrelated transplantation, the role of
HLA and non-HLA genes is critical in the pathophysiology
of GVHD and other outcomes [7, 10, 42]. HLA–DPA1 and
DPB1, which are usually not in linkage disequilibrium with
the other HLA genes [18, 19], are often not considered to be
part of haplotypes and are not systematically characterized
during donor selection [5], although the role of DPB1 has
been well documented [43–45]. In our study, DPB1 mis-
matching is significantly associated with acute GHVD as an
independent factor, albeit only in the univariate setting
(Table 2). The lack of linkage between DPB1 and other loci
observed even in high-frequency haplotypes might account
for the difficulty in demonstrating an impact of these hap-
lotypes on clinical outcome.
Furthermore, the presence of polymorphisms in the so
called “identical HLA haplotypes” is demonstrated by
routine typing with NGS, because this methodology reveals
many new polymorphisms in exons not encoding the pep-
tide binding region, as well as in non-coding regions. There
is no reason to believe that the situation is different outside
HLA genes across chromosome 6. Indeed, the impact of
non-HLA genes (e.g. cytokines, cytokine receptors) and
polymorphisms such as microsatellites and SNPs has been
reported to influence clinical outcome in unrelated HSCT
[6, 8, 9, 11, 12, 46]. Although SNPs can directly affect the
sequences of immunogenic peptides leading to mHA dis-
parities, they may also modify genes encoding proteins
involved in the pathophysiology of GVHD, such as TNF
alpha, complement, TAP1/2, LMP1/7.
One important limitation of our study resides in the small
number of transplanted patients, although it is close to the
number of patients included in the seminal study of
Petersdorf et al., which did not allow testing the putative
effect(s) of individual haplotypes. Moreover, because the
Swiss population is highly heterogeneous, we may lack
statistical power to detect modest effects of haplotype
matching. Therefore, our results can perhaps not be gen-
eralized to countries characterized by lower levels of
diversity.
In conclusion, our study establishes the list of haplotypes
observed in Switzerland, which shows a high population
diversity despite its small size [30]. As expected, we
observe that frequent haplotypes are strongly associated
with a high probability to find a 10/10 matched unrelated
donor. On the other hand, our results support the hypothesis
that haplotype matching does not impact the clinical out-
come and that more evidences are needed to better under-
stand the numerous factors involved.
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